Accelerate Autoimmune Therapies: Join Our Webinar on Biomarker Strategies
Hey folks! Developing new therapies for autoimmune diseases like RA and lupus is a significant challenge, despite a $160B+ global market need. Many translational teams struggle to build a robust biomarker strategy, leading to delays in IND filings and trial initiation. Our upcoming session will show how a distinctive combination of technology and expertise equips your team to:
Validate the most impactful biomarker endpoints for your specific drug candidate.
Integrate patient-reported outcomes (PROs) with biomarkers to lower trial cost and reduce patient burden.
Design an informed, de-risked Phase 1 trial that accelerates your path to approval.
To share how leading biopharma teams are building these data-driven strategies, we invite you to this session. Register Now to request your invite